NEW YORK – JP Morgan said on Monday afternoon that it is downgrading Illumina from an 'overweight' to a 'neutral' rating following Illumina's announcement earlier in the day that it plans to acquire cancer diagnostics company Grail for $8 billion in stock and cash. The investment bank also lowered its December 2021 price target for Illumina from $390 to $280.